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Background: Toxic shock syndrome (TSS) is caused by an overwhelming host-mediated response to bacterial
superantigens produced mainly by Staphylococcus aureus and Streptococcus pyogenes. TSS is characterized by
aberrant activation of T cells and excessive release of pro-inflammatory cytokines ultimately resulting in capillary
leak, septic shock, multiple organ dysfunction and high mortality rates. No therapeutic or vaccine has been
approved by the U.S. Food and Drug Administration for TSS, and novel therapeutic strategies to improve clinical
outcome are needed. Mesenchymal stromal (stem) cells (MSCs) are stromal cells capable of self-renewal and
differentiation. Moreover, MSCs have immunomodulatory properties, including profound effects on activities of T
cells and macrophages in specific contexts. Based on the critical role of host-derived immune mediators in TSS, we
hypothesized that MSCs could modulate the host-derived proinflammatory response triggered by Staphylococcal
enterotoxin B (SEB) and improve survival in experimental TSS.
Methods: Effects of MSCs on proinflammatory cytokines in peripheral blood were measured in wild-type C57BL/6
mice injected with 50 μg of SEB. Effects of MSCs on survival were monitored in fatal experimental TSS induced by
consecutive doses of D-galactosamine (10 mg) and SEB (10 μg) in HLA-DR4 transgenic mice.
Results: Despite significantly decreasing serum levels of IL-2, IL-6 and TNF induced by SEB in wild-type mice,
human MSCs failed to improve survival in experimental TSS in HLA-DR4 transgenic mice. Similarly, a previously
described downstream mediator of human MSCs, TNF-stimulated gene 6 (TSG-6), did not significantly improve
survival in experimental TSS. Furthermore, murine MSCs, whether unstimulated or pre-treated with IFNγ, failed to
improve survival in experimental TSS.
Conclusions: Our results suggest that the immunomodulatory effects of MSCs are insufficient to rescue mice from
experimental TSS, and that mediators other than IL-2, IL-6 and TNF are likely to play critical mechanistic roles in the
pathogenesis of experimental TSS.* Correspondence: kevin.kain@uhn.ca
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Toxic shock syndrome (TSS) is a potentially fatal disease
characterized by systemic capillary leak, commonly associ-
ated with hypoalbuminaemia, edema, hypotension, acute
respiratory distress syndrome, and multiple organ dysfunc-
tion syndrome [1]. TSS is induced by exposure to bacterial
superantigens produced predominantly by Gram-positive
cocci, especially Staphylococcus aureus and Streptococcus
pyogenes [1,2]. Conventional antigens are processed by
antigen presenting cells (APC) into small peptides and pre-
sented within the MHC class II molecule on the surface of
APCs to T cells. As a result, only a small fraction (<0.01%)
of host T cell clones become activated [1]. In contrast,
superantigens bypass antigen processing and bind directly
to MHC class II/T cell receptor as whole antigens, activat-
ing up to 25% of total T cells in the host [1,3]. This results
in excessive and uncoordinated production and release of
pro-inflammatory cytokines, such as TNF, IL-6, IFNγ, IL-2,
and ΙL-1β, which have been implicated in the pathogenesis
of TSS [4-7], including capillary leak, septic shock, multiple
organ dysfunction and death.
While several experimental therapeutics are being in-
vestigated, none has been approved by the U.S. Food
and Drug Administration (FDA) for the treatment of TSS.
As a result, mortality remains high especially in strepto-
coccal TSS (30-50% mortality) compared to staphylococ-
cal TSS (5-10% mortality) [8-10]. In addition, multiple
potential routes of exposure, including epithelial surfaces,
intestinal mucosa and inhalation, make superantigens a
candidate for use in biological warfare [11]. Current clin-
ical management for TSS mainly involves supportive ther-
apy incorporating fluid resuscitation and vasopressors,
and appropriate antibiotics [1]. Overall, there is an urgent
need for a therapeutic strategy that targets the patho-
logical process of TSS.
Mesenchymal stem cells (MSC) are a heterogenous sub-
set of non-hematopoietic pluripotent stromal cells that can
differentiate into multiple cell types of mesenchymal lineage
(i.e., osteoblasts, chondroblasts and adipocytes) [12]. MSCs
have been reported to improve tissue injury arising from
multiple causes, including sepsis, acute renal failure, acute
myocardial infarction and acute lung injury [13-16]. While
the beneficial effects of MSCs were initially attributed to
their pluripotency, the contribution of MSCs to tissue
repair through engraftment and transdifferentiation into
functionally relevant tissues remains unclear [17]. Increas-
ing evidence indicates that MSCs can exert profound im-
munomodulatory effects that contribute mechanistically to
the attenuation of tissue injury via suppression of immune
effector cells, including T cells and macrophages, resulting
in decreased production of proinflammatory cytokines and
chemokines [18-22].
Based on the critical role played by the host immune
response in the pathogenesis of TSS, we hypothesizedthat MSCs would decrease inflammation and improve
survival in experimental TSS. Human MSCs significantly
reduced the serum levels of IL-2, IL-6 and TNF, triggered
by SEB in wild-type mice, while IFNγ was unaffected by
hMSCs. Importantly, MSCs either human or mouse failed
to improve survival in experimental TSS suggesting that
their immunosuppressive effects are insufficient to reduce
mortality in this model.
Methods
Reagents
SEB and D-(+)-galactosamine hydrochlorde (D-gal) were
obtained from Sigma Aldrich (Oakville, ON, Canada).
Recombinant human TSG-6 (rhTSG-6) was purchased
from R&D Systems (Minneapolis, MN, USA). rhTSG-6
(30 μg/mouse) was administered to mice one hour prior
to the D-gal injection.
Mice
Wild-type male 8–10 week old C57BL/6 mice (Jackson
Laboratory, Bar Harbor, Maine, USA) were used for the
measurement of cytokines after SEB injection. For all sur-
vival analyses, 8–10 week old male C57BL/6 mice trans-
genic for HLA-DR4 (Taconic Farms, Inc., New York, NY,
USA) were used [23].
TSS was induced in mice transgenic for HLA-DR4 by
intraperitoneal injection of 10 mg of D-(+)-galactosamine
hydrochlorde (Sigma-Aldrich Canada Ltd., Oakville, ON,
Canada) followed, 1 hour later, by intraperitoneal injec-
tion of SEB (10 μg/mouse, Sigma-Aldrich Canada Ltd.,
Oakville, ON, Canada) [24]. Mice were monitored every
30 minutes during the first 5 hours, and continually
once lethargy became apparent and progressive, at
which time the mice were euthanized.
Ethics statement
All experimental procedures were performed in accord-
ance with the Canadian Council on Animal Care Guide-
lines, and were approved by the Toronto General Hospital
Animal Care Committee at the University Health Network,
Toronto, Canada.
MSC culture
Frozen vials of murine MSCs (mMSCs) and human
MSCs (hMSCs) were obtained from the Texas A&M
Health Science Center College of Medicine Institute for
Regenerative Medicine at Scott & White (Temple, TX,
USA), under the auspices of a National Institutes of Health/
National Centre for Research Resources (NIH/NCRR) grant
(#P40RR017447). All MSCs were reported by the Center as
meeting MSC- defining criteria proposed by the Inter-
national Society for Cellular Therapy (ISCT) [25].
mMSCs (isolated from male C57BL/6 mice) were
thawed and plated for 24 hours in Complete Growth
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bonucleosides and supplemented with antibiotics, 10%
fetal bovine serum (FBS) (Atlanta Biologicals, Miami,
FL, USA) and 10% horse serum (Gibco, Carlsbad, CA,
USA)). hMSCs (isolated from a 24 year old male donor)
were thawed and plated for 24 hours in α-MEM, without
ribonucleosides or deoxyribonucleosides, supplemented
with 2mM L-glutamine, penicillin and streptomycin and
16.5% FBS. After 24 hours, mMSCs or hMSCs were trypsi-
nized and re-plated at 60 cells/cm2. mMSCs/hMSCs were
incubated for each subsequent passage until they reached
70% confluency. Passage 6 (P6) mMSCs or Passage 3 (P3)
hMSCs were washed and resuspended in PBS. 2.5 × 105
hMSCs or mMSCs or PBS alone was administered into
mice intravenously via tail vein one hour prior to induc-
tion of TSS (hMSCs, mMSCs) or three hours after induc-
tion of TSS (mMSCs). For ex-vivo IFNγ pre-treatment of
mMSCs, mMSCs were incubated in complete growth
media containing 100 U/ml of mouse recombinant IFNγ
for 3 hours, washed and resuspended in PBS before being
injected into mice one hour before induction of TSS.
Differentiation assays
MSCs were differentiated into adipocytes, osteocytes
and chondrocytes using the Mouse MSC Functional
Identification kit for murine MSCs (R&D Systems,
Minneapolis, MN, USA) and StemPro Differentiation
Kit (Gibco, Carlsbad, CA, USA) for human MSCs ac-
cording to the manufacturers’ protocols. Briefly, MSCs
were cultured in 12-well plates in α-MEM containing 20%
FBS (Atlanta Biologicals, Miami, FL, USA), L-glutamine,
penicillin and streptomycin until they reached 100% con-
fluency for adipocytic differentiation, and 50-70% con-
fluency for osteocytic and chondrocytic differentiation.
MSCs were cultured in adipogenic, osteogenic or chon-
drogenic media for 7 – 21 days before being prepared for
lineage-specific stains. Adipocytic differentiation was con-
firmed by staining with Oil Red O (Sigma-Aldrich Canada
Ltd., Oakville, ON, Canada) as previously described [26].
Briefly, cells were washed with PBS and fixed in 10%
formalin for 45 minutes. Fixed cells were incubated in
60% isopropanol for 5 minutes before being incubated in
a freshly prepared Oil Red O solution for 15 minutes.
Differentiation to osteocytes was confirmed by Alizarin
Red S staining (Sigma-Aldrich Canada Ltd., Oakville, ON,
Canada) [26]. Cells were washed and fixed as described
above. Fixed cells were stained with 2% Alizarin Red S
solution (w/v, pH4.2) for 20 minutes. For chondrocytic
differentiation, spheroids of 3×105 MSCs were allowed to
form overnight in α-MEM media containing FBS, L-
glutamine and antibiotics in 15mL conical polypropylene
tubes. After being incubated in chondrogenic differenti-
ation media for 21 days, each spheroid in 200 μl media
was transferred to a cytospin sample chamber (ThermoScientific, Mississauga, ON, Canada) attached to a glass
slide, and centrifuged at 800 RPM for 10 minutes. The
cells on glass slides were washed with PBS and fixed in
10% formalin for 1 hour before being incubated with
0.03% (w/v) Alcian Blue 8 GX (Sigma-Aldrich Canada
Ltd., Oakville, ON, Canada) prepared in 60% ethanol and
40% acetic acid. After being stained overnight, cells were
washed in destaining solution containing 60% ethanol and
40% acetic acid. Images of the stained cytospins were ob-
tained by using a digital camera. Microscopic images of
the stained chondrocytes were obtained by using a phase
contrast microscope (oil immersion, magnification ×100).
Serum cytokine measurement
Wild-type C57BL/6 mice were injected with 50 μg of SEB,
and serum was collected 2, 4, 6, 8, 10, 12 and 24 hours
later via cardiac puncture. Serum levels of IL-2, IL-6, TNF
and IFNγ were measured by specific ELISAs (for IL-2 and
IL-6, R&D Systems, Minneapolis, MN, USA; for TNF and
IFNγ, eBioscience, San Diego, CA, USA).
Statistical analysis
Statistical analyses were performed using the GraphPad
Prism software (LaJolla, CA, USA). Statistical significance
for survival studies was assessed by the log-rank test.
Comparison of two groups at multiple time-points was
performed by 2-Way ANOVA, and for a single time-
point, by Mann–Whitney. In all cases, a p-value < 0.05
was considered significant.
Results
Administration of hMSCs suppresses proinflammatory
cytokine production induced by SEB in vivo
In order to ensure their pluripotent potential, P3 hMSCs
were differentiated and we show that these cells differenti-
ated into the three predominant mesenchymal lineages:
adipocytes, osteocytes and chondrocytes (Figure 1).
MSCs have been shown to suppress production of pro-
inflammatory cytokines and chemokines, including
MIP-2(CXCL-2), CCL5, TNF, IL-6, and IL-1β, in animal
models of lung injury and sepsis [16,18,22,27]. There-
fore, we investigated whether hMSCs could modulate
production of pro-inflammatory cytokines, including
IL-2, IL-6, TNF and IFNγ previously implicated in the
pathogenesis of experimental models of TSS [6,7,28-31].
Serum was collected from mice treated with hMSCs, or
PBS as a control, at 2, 4, 6, 8, 10, 12 and 24 hours after
peritoneal injection of SEB, and the serum levels of IL-
2, IL-6, TNF and IFNγ were measured. Serum levels of
all four cytokines rapidly increased following SEB injec-
tion, with the induction of IL-2, IL-6 and TNF preced-
ing that of IFNγ (Figure 2A-D). Importantly, the levels
of IL-2, IL-6 and TNF were significantly different between
the PBS- and hMSC-treated groups (2-way ANOVA:
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I
Figure 1 Differentiation of Passage 3 hMSCs into adipocytes,
osteocytes and chondrocytes. Phase-contrast microscopy images
of: adipogenic differentiation (A-C; Oil Red O staining of undifferentiated
mMSCs (A) and differentiated adipocytes (C); unstained differentiated
adipocytes (B)); osteogenic differentiation (D-F; Alizarin Red S staining of
undifferentiated mMSCs (D) and differentiated osteocytes (F); unstained
differentiated osteocytes (E)). (G-I) Alcian Blue staining of cytospins
prepared from undifferentiated mMSCs (G) and differentiated
chondrocytes (H); phase-contrast microscopy image of the Alcian Blue
stained cytopin of differentiated chondrocytes (I).
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was observed between the groups in the level of IFNγ
(Figure 2A, p=0.6332). When the two treatment groups
were compared at different times, the serum levels of IL-
2, IL-6 and TNF were significantly decreased in the
hMSC-treated mice compared to the PBS-treated mice at
2 hours post SEB-injection (Figure 2E-H, p=0.0351(F),
p=0.0048(G), p=0.0062(H)).
Administration of hMSCs fails to improve survival in an
experimental model of fatal staphylococcal TSS
Based on the finding that hMSCs suppressed serum
levels of pro-inflammatory cytokines previously impli-
cated in the pathogenesis of TSS, we hypothesized that
MSCs would improve survival in experimental fatal TSS.
To test this hypothesis, we used transgenic mice that ex-
press a chimeric MHC class II molecule consisting of
HLA-DR-IEα and HLA-DRβ1*0401-1Eβ, which have a
much higher affinity for superantigens than mouse MHC
Class II molecules [23]. Therefore, unlike wild-type mice,
the HLA-DR4 transgenic mice were demonstrated to
develop TSS-like symptoms upon injection of a small
amount of SEB (10 μg), following a sensitizing agent, D-
galactosamine (D-gal) [7,24]. Chau et al. demonstrated
that 100% lethality can be achieved after a single dose of
10 μg of SEB, following the sensitization with 30 mg of
D-gal [24]. As D-gal is not involved in clinical TSS, the
minimum amount of D-gal to achieve lethality was chosen
for our study. The reduced dose of D-gal (10 mg) resultedin 80-90% lethality within 12 hours after the D-gal injec-
tion with 10 μg of SEB. Either SEB or D-gal at the indi-
cated doses was not sufficient to induce lethality on its
own (data not shown). Treatment of mice with hMSCs
one hour prior to the induction of TSS did not signifi-
cantly improve survival in this model (Figure 3).
MSCs can either stimulate or suppress host immune
response depending on the host cytokine environment
[19,32]. Therefore, we hypothesized that the adminis-
tration of a known immune mediator produced by
hMSCs would enable us to directly assess the immune-
modulatory effects of this therapy independent of the
host cytokine environment. TNF-stimulated gene 6 (TSG-
6) is an anti-inflammatory glycoprotein that was shown to
mediate the therapeutic effects of hMSCs in the animal
models of myocardial infarction and zymosan-induced
mouse peritonitis [15,33]. Therefore, we tested whether i.
v. injections of human recombinant TSG-6 could improve
survival in our TSS model. Human and mouse TSG-6
proteins share 92% sequence identity, and human recom-
binant TSG-6 has been shown to inhibit TNF expression
in mouse macrophages in a co-culture experiment, and
reduce inflammatory response and infarct size in a mouse
model of myocardial infarction [15].
Both PBS-treated and TSG-6-treated groups showed
80-90% lethality with the median survival of 6.76 hours,
and there was no statistically significant difference be-
tween these groups (Figure 3B).
Administration of mMSCs also fails to improve survival in
an experimental model of fatal staphylococcal TSS
In order to ensure that the lack of therapeutic efficacy of
MSCs was not attributable to the heterologous use of
human MSCs in a murine model we also examined
whether mMSCs injected one hour prior to the induction
of TSS could improve survival. The pluripotent potential
of P6 mMSCs was confirmed by differentiating them into
adipocytes, osteocytes and chondrocytes (Figure 4). How-
ever, similar to hMSCs we observed no significant survival
benefit between the PBS- and mMSC-treated groups
(Figure 5A). While the exact mechanism determining
the immune suppressive function of MSCs is incom-
pletely understood, multiple studies have underscored
an important role for IFNγ in mediating these effects
[21,32,34]. A previous study has demonstrated that the
induction of IFNγ occurs relatively late in the experi-
mental model of TSS induced by D-gal and SEB, and
that the induction of IFNγ is preceded by the induction
of TNF and IL-2, which is consistent with our observa-
tions (Figure 2) [6]. Therefore, we also assessed the
effects of later administration of mMSCs on survival,
i.e. when injected 3–4 hours after the D-gal injection.
However, delayed mMSC treatment also failed to induce
a survival benefit (data not shown).
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Figure 2 hMSCs suppress proinflammatory cytokine production induced by SEB in vivo. (A-D) Levels of IFNγ (A), IL-2 (B), IL-6 (C) and TNF
(D) were measured from serum collected at the indicated times after SEB was injected in mice pre-treated with hMSCs (white) or PBS as a control
(black). Each bar represents a mean + SEM. Statistical differences between the PBS and hMSC groups were assessed by 2-way ANOVA (p=0.6322
(A), p=0.0014 (B), p=0.0011 (C), p=0.0149 (D), n=5/group/time). Data are representative of two independent experiments. (E-H) Serum levels of
IFNγ (E), IL-2 (F) and IL-6 (G) and TNF (H) at 2hr post-SEB injection were compared between PBS and hMSC groups. Statistical differences were
assessed by the Mann–Whitney test. Data represent a pooled result of two independent experiments. n.s.=not significant.
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http://www.biomedcentral.com/1471-2172/15/1Given the importance of IFNγ in eliciting an immuno-
suppressive phenotype of MSCs, we also investigated
whether pre-treatment of mMSCs ex vivo with IFNγ
prior to their injection into mice could improve survival.
A previous study demonstrated that 100 U/ml of IFNγ
represents a threshold above which mMSCs switch froman antigen-presenting phenotype to an immunosuppres-
sive phenotype [32]. Therefore, we treated mMSCs with
100 U/mL of mouse IFNγ for 3 hours before harvesting
them for injections. While there was a trend of increased
median survival, this difference failed to reach statistical
significance (Figure 5B).
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Figure 3 Neither hMSCs nor TSG-6 improve survival in
experimental fatal staphylococcal TSS. Kaplan Meyer survival
curves are shown for HLA-DR4 mice which were treated with
2.5×105 hMSCs (A, dotted line, diamond), human recombinant TSG-6
(B, dotted line, diamond) or PBS (A, B solid, square) one hour prior
to the induction of TSS. Statistical differences were assessed by log-
rank test (p=0.7327 (A), p=0.7258 (B), n=20-22/group). Data
represent a pooled result from two independent experiments.
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Figure 4 Differentiation of Passage 6 mMSCs into adipocytes,
osteocytes and chondrocytes. Phase-contrast microscopy images
of: adipogenic differentiation (A-C; Oil Red O staining of undifferentiated
mMSCs (A) and differentiated adipocytes (C); unstained differentiated
adipocytes (B)); osteogenic differentiation (D-F; Alizarin Red S staining of
undifferentiated mMSCs (D) and differentiated osteocytes (F); unstained
differentiated osteocytes (E)). (G-I) Alcian Blue staining of cytospins
prepared from undifferentiated mMSCs (G) and differentiated
chondrocytes (H); phase-contrast microscopy image of the Alcian Blue
stained cytospin of differentiated chondrocytes (I).
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This study used an experimental model to investigate
the therapeutic potential of MSCs for TSS. We show
that hMSCs suppressed circulating serum levels of IL-2,
IL-6 and TNF induced by SEB, but not that of IFNγ.
However, the immunomodulatory effect of hMSCs was
insufficient to confer a survival benefit in a murine
model of fatal TSS. Consistent with this finding, a down-
stream mediator produced by hMSCs, TSG-6, also failed
to improve survival in experimental TSS. mMSCs were
similarly incapable of improving survival even when pre-
treated with IFNγ, which is thought to promote the
immunosuppressive phenotype of MSCs [32]. Collect-
ively, our data suggest that MSCs are unlikely to provide
a therapeutic benefit against TSS despite their immune
suppression of at least some of the implicated mediators
of TSS.Several novel treatment strategies for TSS have been
proposed and are under investigation. Firstly, inhibiting
the interaction of superantigens with the T cell receptor
and MHC II has been explored by using peptide mi-
metics of superantigens [35,36], protein chimeras of the
binding sites of superantigens [37], and nucleic acid apta-
mers which specifically bind superantigens [38]. Secondly,
inhibitors have been developed against the key mediators
of pro-inflammatory intracellular signaling pathways or
pro-inflammatory cytokines and chemokines themselves
[39-44]. Some of the experimental therapeutics have been
previously approved by the FDA for other indications,
receiving particular attention especially for biodefence
purposes (e.g. rapamycin, dexamethasone, pentoxifylline)
[42-45]. Finally, proof of concept of neutralizing superanti-
gens by intravenous immunoglobulins (IVIg) has been
demonstrated, and different recombinant antibodies are
being investigated for their neutralizing potential although
challenges remain with consistent neutralization of differ-
ent superantigens [2,46-49].
The capacity of MSCs to suppress immune effector
cells such as macrophages and T cells and their secreted
mediators, as well as the relative ease of the isolation of
MSCs from bone marrow, have brought much attention
to the potential therapeutic application of MSCs to a
range of human diseases. Among different models of dis-
eases, therapeutic benefits of MSCs have mostly been re-
ported in mouse models of acute lung injury and sepsis
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Figure 5 mMSCs fail to improve survival in experimental fatal
staphylococcal TSS with or without pre-treatment with IFNγ.
Kaplan Meyer survival curves are shown for HLA-DR4 mice which were
treated with 2.5×105 untreated mMSCs (A, dotted line, diamond),
IFNγ-treated mMSCs (B, dotted line, diamond) or PBS (A, B solid line,
square) one hour prior the induction of TSS. Statistical differences were
assessed by log-rank test (p=0.4280 (A), p=0.2184 (B), n=20-22/group).
Data represent a pooled result from two independent experiments.
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ther alone or with an antibiotic, improved survival and
organ dysfunction, which was associated with reduced
levels of pro-inflammatory cytokines (e.g., TNF, IL-6), che-
mokines, (e.g., CXCL2, CCL5 and KC/IL-8) in the periph-
eral blood and/or bronchoalveolar lavage fluid [16,18,22].
Our observation that hMSCs can suppress IL-2, IL-6 and
TNF but not IFNγ is consistent with a previous finding in
which administration of mMSCs reduced serum levels of
IL-6 and TNF but not that of IFNγ in a cecal ligation and
puncture model of sepsis [18].
Of note, the observed immunosuppressive effects on
IL-2, IL-6 and TNF were not associated with an im-
proved survival in experimental TSS in our study. There
are several possible explanations for this observation.
First, the difference in the host immune environment in
the two models used for monitoring cytokine levels and
for monitoring survival may result in a difference in the
immunomodulatory properties of MSCs. MSCs are known
to be highly sensitive to the host immune environment
that can promote either an antigen presentation pheno-
type or alternatively, an immunosuppressive phenotype[19]. In our study, cytokine measurements were deter-
mined in wild-type C57BL/6 mice, in which only SEB was
used to trigger TSS-like host immune response whereas
the survival outcome was monitored in a lethal model of
TSS, which required a sensitizing agent, D-gal, in addition
to SEB.
It is possible that in the lethal model of TSS, the host
immune environment is not optimal for inducing the
immunosuppressive properties of hMSCs as in the non-
lethal wild-type model. Alternatively, the lack of improve-
ment in survival despite the partial immunosuppression
by hMSCs may suggest that the hMSC-mediated im-
munosuppression does not affect the critical pathways
and mediators for TSS-associated lethality. This latter hy-
pothesis is supported by a recent report in which a neu-
tralizing antibody against IFNγ significantly improved
survival in SEB-induced TSS in HLA-DR3 mice, and the
improved survival was associated with a reduction in the
serum levels of chemokines, RANTES (CCL5) and KC
(mouse CXCL1) [34]. Furthermore, in several earlier stud-
ies, therapeutic strategies that improved survival against
experimental TSS were associated with suppression of
IFNγ [41-43]. In our study, the suppressive effects of
hMSCs were limited to IL-2, IL-6 and TNF, with no effect
on IFNγ. The lack of effect of MSCs on IFNγ has also
been observed by Nemeth et al. in a study where mMSCs
significantly improved survival against experimental sepsis
by reducing serum levels of TNF, and IL-6, but not IFNγ
[18]. Previous findings by Tilahun et al. and others suggest
that targeting IFNγ and its downstream mediators (e.g.
CCL5, CXCL1) may be crucial in conferring a significant
protection against experimental TSS [34,41-43].
There are limitations to our study. As an experimental
model of human TSS, the HLA-DR4 transgenic mouse
model requires D-gal as a sensitizing agent which induces
an acute response that shares some but not all features of
human TSS. A more recent model reported by Tilahun
et al. uses HLA-DR3 transgenic mice in which lethality is
induced without the need of a sensitizing agent [34], how-
ever, these mice are not commercially available. Directly
correlating the immunomodulatory effects of MSCs with
survival requires a time-course study examining cytokine
levels in the lethal model used. However, there were tech-
nical constraints to sample appropriate numbers of ani-
mals given the rapidity of death in this model. Moreover,
due to the requirement for a sensitizing agent in our
model, we postulated that determining the effects of
MSCs on SEB-mediated host immune response in the ab-
sence D-gal in the wild-type mice would be more relevant
to understanding the immunomodulatory effects of MSCs
on SEB-mediated TSS. Lastly, our study did not examine
the effects of MSCs in experimental TSS induced by a
Gram-positive bacterial strain, which may be more rele-
vant to human TSS. Future studies assessing the effects of
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in the HLA-DR3 model may provide additional insight
into the immunomodulatory effects of MSCs on TSS.
The exact mechanism underlying the immunosuppres-
sive effects of MSCs is poorly understood. Each infection
state is characterized by distinct cytokine milieu that is
dynamically regulated throughout the course of infection
and is likely to influence whether MSCs can function as
immunosuppressors in a given model. For instance,
despite their capacity to suppress T cell proliferation
in vitro, MSCs failed to improve clinical outcomes that
are primarily mediated by T-cells in vivo in the models
of heart transplant, graft versus host disease and collagen
induced arthritis [50-52]. Similarly, hMSCs or mMSCs
failed to improve survival in a murine model of severe
influenza [53]. Indeed, in some cases, in vivo administra-
tion of MSCs was associated with increased levels of pro-
inflammatory cytokines and poorer clinical outcome, de-
pending on the dose and the time of administration
[50,51]. In assessing therapeutic potential of MSCs, our
present findings along with others, underscore the import-
ance of elucidating the molecular targets of MSCs in a
particular disease context, and their relevance to the
pathogenesis of the disease.
Conclusions
In summary, our data suggest that MSCs are unlikely to
provide a therapeutic benefit for TSS. While MSCs can
suppress some mediators of TSS, their immune suppres-
sive capacity against TSS may be too limited quantitatively
(i.e., duration and extent of suppression) and/or qualita-
tively (i.e. failure to suppress the critical mediators of TSS)
to significantly alter the clinical outcome.
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